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Influence of Lung Parenchymal
Destruction on the Different Indexes of
the Methacholine Dose-Response Curve
in COPD Patients*
Gert T. Verhoeven, MD; Anton F.M. Verbraak, PhD; Sandra Boere-van der Straat;
Henk C. Hoogsteden, MD, PhD; and Jan M. Bogaard, PhD
Study objectives: The interpretation of nonspecific bronchial provocation dose-response curves in
COPD is still a matter of debate. Bronchial hyperresponsiveness (BHR) in patients with COPD could
be influenced by the destruction of the parenchyma and the augmented mechanical behavior of the
lung. Therefore, we studied the interrelationships between indexes of BHR, on the one hand, and
markers of lung parenchymal destruction, on the other.
Patients and methods: COPD patients were selected by clinical symptoms, evidence of chronic,
nonreversible airways obstruction, and BHR, which was defined as a provocative dose of a substance
(histamine) causing a 20% fall in FEV1 (PC20) of < 8 mg/mL. BHR was subsequently studied by
methacholine dose-response curves to which a sigmoid model was fitted for the estimation of plateau
values and reactivity. Model fits of quasi-static lung pressure-volume (PV) curves yielded static lung
compliance (Cstat), the exponential factor (KE) and elastic recoil at 90% of total lung capacity
(P90TLC). Carbon monoxide (CO) transfer was measured with the standard single-breath method.
Results: Twenty-four patients were included in the study, and reliable PV data could be obtained from 19.
The following mean values ( 6 SD) were taken: FEV1, 65 6 12% of predicted; reversibility, 5.6 6 3.1% of
predicted; the PC20 for methacholine, 4.3 6 5.2 mg/mL; reactivity, 11.0 6 5.6% FEV1/doubling dose;
plateau, 48.8 6 17.4% FEV1; transfer factor, 76.7 6 17.9% of predicted; transfer coefficient for carbon
monoxide (KCO), 85.9 6 22.6% of predicted; Cstat, 4.28 6 2.8 kPa; shape factor (KE), 1.9 6 1.5 kPa; and
P90TLC, 1.1 6 0.8 kPa. We confirmed earlier reported relationships between Cstat, on the one hand,
and KE (p < 0.0001), P90TLC (p 5 0.0012), and KCO percent predicted (p 5 0.006), on the other
hand. The indexes of the methacholine provocation test were not related to any parameter of lung
elasticity and CO transfer.
Conclusion: BHR in COPD patients who smoke most probably is determined by airways pathology
rather than by the augmented mechanical behavior caused by lung parenchymal destruction.
(CHEST 2000; 117:984–990)
Key words: bronchial provocation tests; COPD; dose-response relationship; forced expiratory flow rates; human; lung
compliance; lung volume measurements; methacholine bromide/diagnostic use; pulmonary diffusing capacity
Abbreviations: BHR 5 bronchial hyperresponsiveness; CO 5 carbon monoxide; Cstat 5 static lung compliance; FRC 5
functional residual capacity; IVC 5 inspiratory vital capacity; KCO 5 transfer coefficient for carbon monoxide; KE 5 shape
factor; LE 5 linear-exponential; PC20 5 provocative concentration of a substance causing a 20% fall in FEV1;
P90TLC 5 elastic recoil pressure at 90% of total lung capacity; PV 5 pressure-volume; TLC 5 total lung capacity;
Tlco 5 transfer factor for carbon monoxide.
B ronchial hyperresponsiveness (BHR) is presentin patients with asthma and COPD.1 Approxi-
mately half of the subjects with COPD in a general
population have BHR.2 In the Lung Health Study,3
BHR was noted in 85.1% of the women and 58.9% of
the men with mild-to-moderate airflow limitation.
The estimation of BHR is important for the diagnosis
of asthma and for determining asthma severity,
whereas the meaning of BHR for the clinical man-
agement of COPD is still unclear.4 COPD patients
with BHR appear to be prone to a more rapid
decline of their FEV1.5
Clinical studies suggest that BHR in patients with
COPD differs from BHR in patients with asthma.6–9
For example, in patients with COPD, BHR for
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physiologic stimuli (eg, cold air) usually is not found
in the presence of BHR for pharmacologic agents
(eg, histamine). In patients with asthma, both types
of stimuli cause bronchoconstriction.6,7 The explana-
tion for these differences might be found in the
different pathologic changes in the airways and in
the lung parenchyma of asthma and COPD pa-
tients.1 The main and clearest difference between
asthma and COPD is destruction of the lung paren-
chyma in COPD, leading to emphysema and loss of
lung elasticity. In patients with COPD, compared to
those with asthma, there is a relationship between
baseline FEV1 and the level of BHR.8,9 The FEV1 is,
however, not a good predictor of the amount of
parenchymal destruction and loss of elastic re-
coil.10–13 The most reliable test for lung elasticity is
the direct estimation of quasi-static esophageal pres-
sure-volume (PV) curves.10,11,14 The destruction of
parenchymal tissue also is shown by the impairment
of carbon monoxide (CO) transfer.15–18 We per-
formed these lung function tests in COPD patients
who smoked, who fulfilled the established clinical
and functional criteria for COPD, and who also had
a provocative concentration of a substance (hista-
mine) causing a 20% fall in FEV1 (PC20) of # 8
mg/mL. In subsequent methacholine dose-response
curves, not only PC20 (sensitivity) but also maximal
bronchoconstriction (plateau) and the slope of the
curve (reactivity) were estimated, because these
factors should yield additional information on the
causative mechanisms of BHR.19
The aim of our study was to investigate the
influence of the impairment of lung parenchymal
structure on BHR by the estimation of the interre-
lationships between indexes related to lung paren-
chymal destruction (lung elasticity and CO transfer)
and indexes from methacholine log-dose response
curves.
Materials and Methods
COPD patients were recruited according to generally accepted
clinical and functional criteria.20 The inclusion criteria were the
following: chronic productive cough; age between 40 and 70
years; current smokers; negative skin tests for standard inhalation
allergens; FEV1 or FEV1/inspiratory vital capacity (IVC) ratio
# 70% of the predicted normal value; reversibility of FEV1 of
, 10% predicted after 750 mg terbutaline administered by
metered-dose inhalation; and nonspecific BHR, defined by a
PC20 for histamine of # 8 mg/mL. Exclusion criteria were the
following: a history of asthma; complaints of wheezing; radio-
graphic signs of bullous emphysema; recent respiratory tract
infection; and recent or concurrent usage of anti-inflammatory
drugs. Eligible patients refrained from oral anti-inflammatory
medication at least 3 months and from inhaled glucocorticoids for
at least 6 weeks before the start of the study.
The study was approved by the Medical Ethics Committee of
the University Hospital Dijkzigt, and written informed consent
was obtained from all participants.
Functional tests included the following: spirometry (total lung
capacity [TLC], functional residual capacity [FRC], RV, IVC,
FEV1); reversibility test (FEV1 percent predicted); single-breath
CO transfer (transfer factor of the lung for CO [Tlco] and
transfer coefficient for CO [KCO]); and PV curves. Spirometry
was measured with the multiple-breath, closed Helium wash-in
method, using a water-sealed spirometer (model D53R; Lode;
Groningen, The Netherlands) and with the patient in sitting
position. The lung volumes were corrected to body temperature
and ambient pressure, saturated with water vapor. All reference
values were derived from the standards of the European Com-
munity for Steel and Coal.21,22
Histamine and methacholine provocation tests were performed
according to the 2-min tidal breathing method that was first
described by Cockcroft et al.23,24 The PC20 for histamine was
used as an inclusion criterion. Because of lesser side effects,
methacholine was used for obtaining as complete as possible
dose-response curves.25 After inhalation of an isotonic saline
solution, doubling concentrations of histamine-sulfate or acetyl-
b-methylcholine-bromide were administered, starting with doses
of 0.03 mg/mL. Methacholine was prepared by our hospital
pharmacy department. Solutions were stored at 4°C and were
used at room temperature. Aerosols were generated by a nebu-
lizer (model 646; DeVilbiss Co; Somerset, PA) (measured output,
0.13 mL/min) and were inhaled by tidal breathing over a 2-min
period at 5-min intervals. The response to methacholine or
histamine was measured as the change in FEV1 expressed as a
percentage of the initial value. The histamine provocation test
was interrupted if a 20% fall in FEV1 occurred before or at a dose
of 8 mg/mL. The methacholine tests were continued up to a
concentration of 256 mg/mL but were interrupted if the FEV1
fell by . 60% or if unpleasant side effects occurred.
From the methacholine provocation tests, the log2 concentra-
tion and the measured percentage of changes in FEV1 were
imported to a computer program that fitted a sigmoid function
(cumulative Gaussian distribution) to the data.26 Reactivity (the
slope of the curve), and plateau values (maximal bronchoconstric-
tion) were taken from this model fit, whereas the PC20 was
calculated from the measured data by linear interpolation of
adjacent data points.
The lung elasticity measurements were performed immedi-
ately after the reversibility test. This sequence was chosen for
reasons of standardization and in order to minimize the poten-
tially disturbing effect of airway closure on lung elasticity.
Quasi-static deflation exercises were performed according to the
method that has been described before.27 In short, the transpul-
monary pressure was measured via a transducer (model P45;
Validyne Engineering Corp; Northridge, CA) coupled to a bal-
loon that was positioned in the lower third of the esophagus. The
simultaneous recording of volume changes was obtained during a
slow expiration (ie, expiration not exceeding 0.3 L/s). Selected
curves were smoothed by drawing a line by hand through
catacrotic points of the cardiac pulsations on the curve. Volume
data were obtained at equal transpulmonary pressure intervals,
yielding an average of 10 to 30 data points up to the TLC level.
A linear-exponential (LE) and an exponential model were fitted
to the measured data. The LE model gave the most accurate fit
to experimental curves and was, therefore, used for the estima-
tion of static lung compliance (Cstat) and volume-dependent
recoil pressures.27,28 For this fit, the curve was considered to be
composed of a linear part, from the first data points on starting at
the FRC level, and an exponential part, starting at the higher
volume level. Cstat was obtained from the linear part if four or
more data points contributed to that part. In a minority of cases,
we calculated Cstat by hand as the slope between FRC and
FRC 1 0.5 L. The elastic recoil pressure at 90% of TLC
(P90TLC) also was derived from the LE model fit. This pressure
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index was considered to be the elastic recoil index with the lowest
variation coefficient.29 Additionally, we prefer to use the P90TLC
values above the recoil pressure at TLC because P90TLC is less
dependent on inspiratory muscle force. The shape factor (KE)
was determined from the following generally used exponential
equation:
V 5 Vmax{1 2 exp[KE(P 2 P0)]}
where Vmax is the asymptotic value (in liters) and P0 is the
intercept with the P axis at V 5 0 kPa.
KE can be considered as an elasticity index, independent of
lung size.28 For the fit with the exponential model, we used the
same (measured) input data as for the LE model fit. KE was
considered as an additional elasticity index.
Linear regression analysis between variables, pairwise multi-
variate correlation, and statistical significance were calculated
with the use of a package of statistical software (Statistical
Graphics Corp; Rockville, MD). Test results were considered
statistically significant at p , 0.05.
Results
Twenty-four patients were included in the study.
From 19 patients, we obtained reliable PV curves;
the remaining patients did not tolerate the esopha-
gus balloon long enough or showed effects of swal-
lowing that hampered an accurate interpretation of
the data. The mean age of the patients was 56 years
(Table 1). The mean FEV1 was 65% of predicted.
One patient had an FEV1 . 70% of predicted but
was included because his FEV1/IVC ratio was 0.51.
The mean reversibility of FEV1 after terbutaline
inhalation was 5.6%. Four patients showed no re-
versibility at all.
The patients had moderate or severe BHR (Table
1). The mean PC20 for methacholine was higher than
that for histamine (4.3 vs 1.7 mg/mL, respectively).
This difference also was reported in an earlier study
of smokers with mild chronic airflow limitation.30
After correction for the difference in molecular-
weight (1 mg of the bromide compound is equivalent
to 0.82 mg of the chloride compound), the corrected
mean bromide value of the PC20 became 3.5 mg/mL.
The mean plateau value was 48.8% of the FEV1.
In Figure 1, we present a curve in which the fitted
plateau is almost equal to the measured data (Fig 1,
top) and a curve in which the plateau value is derived
from extrapolation (Fig 1, bottom). If the experimen-
tal plateau estimate was defined by the mean value of
the last two provocative concentrations with a varia-
tion of , 5%, we observed that the fitted plateau was
almost equal to the experimental plateau estimate in
13 of the 24 dose-response curves.
Cstat ranged from 1.06 to 10.52 kPa, which indi-
cates a range from moderately low to clearly in-
creased if a normal range of 1.5 to 2.5 kPa is taken
into account.21 Mean Cstat was 4.6 kPa (Table 1).
Tlco was between 34% of predicted and 106% of
predicted, and KCO ranged from low (43% of pre-
dicted) to higher than normal (139% of predicted).
Statistically significant correlations existed among
all the parameters of the PV curve (Table 2). The
strongest correlation was between Cstat and KE
(R 5 0.81; p , 0.0001). The KCO percent predicted
correlated strongly with Cstat (R 5 20.60;
p 5 0.006; Table 2) but not with KE and P90TLC.
The Tlco percent predicted showed no significant
correlation with Cstat, KE, or P90TLC.
The indexes of BHR (PC20, reactivity, and plateau
value) were tested for correlation with the indexes of
the PV curve (Cstat, KE, and P90TLC), CO transfer
(Tlco and KCO), and FEV1. In Table 3, we present
the correlations between Cstat and the BHR in-
Table 1—Smoking Habits, FEV1, Reversibility, BHR, CO Transfer, and Lung Elasticity Data
Data No. of Patients Mean 6 SD Median Range
Age, yr 24 55.5 6 8.5 54 42–69
Actual smoking, cigarettes/d 24 15.6 6 6.8 13 6–30
Pack-years 24 23 6 10.5 23 5–50
FEV1, % predicted 24 64.5 6 11.9 65 34–93
Reversibility, % predicted 24 5.6 6 3.1 5.5 0–9.8
PC20
Histamine 24 1.66 6 2.00 0.87 0.11–8
Methacholine 24 4.27 6 5.2 1.46 0.4–17.4
log2 PC20 methacholine 24 1.07 6 1.74 0.53 21.3–4.1
Reactivity, % FEV1/doubling dose 24 11.0 6 5.6 8.98 3.9–26.8
Plateau, %FEV1 24 48.8 6 17.4 48.3 20.8–95.7
Cstat, kPa 19 4.6 6 2.8 4.1 1.1–10.5
KE, kPa 19 2.5 6 1.5 2.2 0.7–6.3
P90TLC, kPa 19 1.1 6 0.8 0.8 0.4–2.7
Tlco, % predicted 24 76.7 6 17.9 75 34–106
KCO, % predicted 24 85.9 6 22.6 86 43–139
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dexes. No significance was found and no significance
was found for the additional elasticity indexes and
diffusion parameters.
There was a significant correlation between the
FEV1 percent predicted, on the one hand, and log2
PC20 for histamine and log2 PC20 for methacholine,
on the other hand (R 5 0.44, p 5 0.024; and
R 5 0.46, p 5 0.023, respectively; Table 3). There
was also a significant (negative) correlation between
the FEV1 percent predicted and reactivity
(R 5 20.52; p 5 0.008; Table 3). The correlation
between the FEV1 percent predicted and the pla-
teau value was not significant (Table 3).
Because smoking is the most important risk factor
for emphysema, we looked at paired correlations
among smoking data, CO transfer, and indexes of the
PV curve. There was a significant correlation only
between KE and the actual number of cigarettes
smoked per day (R 5 0.53; p 5 0.019; Table 2).
Discussion
The aim of our investigation was to study the
interrelationships among indexes describing BHR,
lung elasticity, and CO transfer in patients with
COPD. For the estimation of BHR and the degree
of impairment of lung mechanics, detailed informa-
tion was obtained by fitting models of methacholine
dose-response curves and quasi-static PV curves.
Several mechanisms have been proposed for ex-
plaining enhanced bronchoconstriction as a reaction
to inhaled stimuli.1,19,31 Detailed analysis of metha-
choline log-dose response curves is supposed to offer
additional information on the causative mechanisms
Table 2—Correlations of the Indexes of the PV Curves, CO Transfer, and Smoking by
Pairwise Multivariate Analysis*
Variable 1 Variable 2 No. of Patients R Value p Value
Cstat KE 19 0.821 , 0.0001
Cstat P90TLC 19 20.687 0.0012
Tlco, % predicted Cstat 19 20.290 0.23
Tlco, % predicted KE 19 20.254 0.29
Tlco, % predicted P90TLC 19 0.123 0.62
KCO, % predicted Cstat 19 20.604 0.006
KCO, % predicted KE 19 20.414 0.077
KCO, % predicted P90TLC 19 0.438 0.061
KE Act smoking 19 0.534 0.019
*Act smoking 5 actual smoking (cigarettes/day).
Figure 1. Two examples of sigmoid fitting of the methacholine
provocation tests. Top: the measured data (l) are almost equal
to the fitted plateau. Bottom: the measured data (f) show that
the plateau was not reached during the test.
Table 3—Correlations of the Indexes of BHR With
Quasi-Static Compliance and FEV1 by
Pairwise Multivariate Analysis*
Variable 1 Variable 2 No. of Patients R Value p Value
PC20 hist Cstat 19 0.282 0.24
PC20 meth Cstat 19 0.061 0.82
Reactivity Cstat 19 0.291 0.24
Plateau Cstat 19 0.321 0.19
PC20 hist FEV1 24 0.483 0.01
PC20 meth FEV1 24 0.470 0.02
Reactivity FEV1 24 20.522 0.0075
Plateau FEV1 24 20.194 0.35
*hist 5 histamine; meth 5 methacholine.
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of BHR.19 PC20 and reactivity are considered to be
determined by prejunctional mechanisms, and the
plateau value is more dependent on postjunctional
mechanisms.19 In patients with COPD, both
prejunctional mechanisms (ie, epithelial damage,
neural control, and inflammation) and postjunctional
mechanisms (ie, loss of lung elasticity, swelling of
airway wall, and intraluminal secretions) can be
responsible for the occurrence of BHR. Because
lung elasticity in stable patients with asthma is not
appreciably disturbed, this would be an attractive
explanation for the occurrence of BHR in patients
with COPD and to relate it to the loss of elastic
recoil. Theoretically, a decrease in lung elasticity can
facilitate an amplified bronchomuscular response.31
First, we have studied the functional indexes of
lung parenchymal destruction.
Some degree of emphysema, which is present in
patients with mild COPD, already influences the PV
relationships.10,11,14 A PV curve can be obtained with
relatively simple techniques but has the disadvantage
of being an invasive test. The reproducibility of
estimates, especially of KE, was reported to be good,
at least for healthy adults.29,32,33 KE was found to be
a good indicator for the presence of mild emphyse-
ma.10,15,32 We found that Cstat and P90TLC from
the LE model fit and KE from the exponential
model fit correlated well with each other, indicating
that these indexes were linked to elastic properties of
the lung (Table 2).
An additional index of lung parenchymal destruc-
tion is CO diffusion. Berend et al16 were the first to
report a correlation between CO transfer and sever-
ity of emphysema. Others have confirmed the rela-
tionship between emphysema and KCO.15,17,18 We
found also a significant correlation of Cstat with
KCO (Table 2). KCO can be considered as an index,
related to structural aspects of the lung parenchyma,
whereas Tlco is a measure of overall gas transport.
In this study, we also tested the indexes of the
impairment of lung parenchymal structure for cor-
relation with cigarette smoke exposure, pack-years
and actual smoking. There was a significant correla-
tion of KE only with actual smoking (Table 2). There
are few data about the correlation of smoking with
parenchyma impairment. In one study, there was no
detectable effect of smoking on lung elastic recoil in
healthy men.34 Other investigators have reported a
quantitative relationship between the total exposure
to cigarette smoke and both alveolar and airway
pathologic features in a necropsy study.35 So, al-
though the assumption is plausible that there is a
relationship between cigarette smoke exposure and
loss of elastic recoil, it is not yet clear how this
influences the derivatives of the PV curve. We have
assumed that differences in vulnerability of the lung
parenchyma to cigarette smoke influence the mea-
sured loss of elastic recoil more than the amount of
cigarette smoke exposure.
In patients with a1-antitrypsin deficiency, Cheung
et al36 found a relationship between the loss of elastic
recoil and maximal airway narrowing (plateau). It
should be noted that their patient group was selec-
tive; five of eight patients had an FEV1 . 80% of
predicted, patients were clinically stable, and pa-
tients were ex-smokers or nonsmokers. These pa-
tients seemingly had only parenchymal disease. The
effect of the involvement of airways disease was
shown in a study by Eidelman et al.13 They described
different patterns of mechanical abnormalities be-
tween smoking and nonsmoking patients with a1-
antitrypsin deficiency. In COPD patients, especially
in those who smoke, it is likely that there are both
parenchymal and airway changes. In our study and in
the study by Koyama et al37, no significant correla-
tions were found among indexes of the PV curve, on
the one hand, and BHR, on the other hand. This
means either that PV curves do not represent elastic
recoil changes or that BHR is also influenced by
airway pathology. There are several arguments that
support the last mechanism. First, as discussed
above, indexes of PV curves have been found to
correlate with pathologic assessment of lung paren-
chyma. Second, the significant correlations among
the different indexes of the PV curve, and between
elasticity and KCO, indicate that our results are a
good reflection of the loss of elastic recoil of the
lung. Third, there were significant relationships be-
tween the determinant of airways obstruction
(FEV1) and PC20 (Table 3).
In the present study, not only were the PC20 for
histamine and the PC20 for methacholine correlated
with the FEV1 percent predicted, but also with
reactivity. The first correlation was reported else-
where2,8,9 and was found also by Cheung et al36 and
Koyama et al.37 This indicates that the definition of
PC20 as a 20% fall of the starting FEV1 makes the
outcome highly dependent on measurement of
FEV1 in patients with a low FEV1. Our finding that
reactivity (the slope of the dose-response curve) is
steeper at a lower FEV1 percent predicted, indicates
that reactivity also was hampered by the way in
which the response is expressed. This appeared to be
distinct for the plateau value, which was not corre-
lated with the starting FEV1 (Table 3). The clinical
significance of the level of a plateau value is that it is
a measure of the maximal acute bronchoconstriction
that can be provoked in an individual. The applica-
tion of the plateau value in combination with the
PC20 for methacholine has been suggested for the
distinction between asthma and COPD.1 While
BHR can be found both in patients with asthma and
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patients with COPD when considering PC20, the
plateau value usually is not reached in patients with
moderately severe or severe asthma. In our study of
patients with COPD who have moderately severe
BHR, the plateau was reached in the majority of the
patients, but not in all. It appears, therefore, that the
estimation of the plateau does not always provide a
clear distinction between asthma and COPD.
Because none of the indexes of BHR is related to
any of the functional data of lung elasticity or CO
transfer in COPD patients who smoke, airway pa-
thology determines the response to methacholine at
least to such an extent that it overrules a possible
correlation with parenchymal destruction. The na-
ture and extent of airways disease seem to be more
important for the occurrence of BHR in patients
with COPD than does parenchymal pathology. Tay-
lor et al38 have compared PC20 for methacholine in
vivo with the function of bronchial smooth muscle
strips from surgical specimens. No correlation was
found, which led to their conclusion that smooth
muscle pathophysiologic changes were not responsi-
ble for BHR in COPD. One other study provided
evidence that BHR in patients with emphysema is
related to differences among types of emphysema
and to the cell infiltrate in the airway walls.39
In conclusion, we found no relationship between
the impairment of lung parenchymal structure, ei-
ther from PV curves or CO diffusion, and indexes of
BHR. Nonspecific BHR in COPD patients who
smoke is determined by small airway pathology to
such an extent that it overrules a possible correlation
with parenchymal impairment. The combination of
our findings with those from clinicopathologic stud-
ies suggests that the plateau value (maximal airway
constriction) is a better indicator of small airways
pathologic changes than are PC20 and reactivity.
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